Lurasidone in the treatment of sleep disturbance associated with bipolar depression: post-hoc analysis of a placebo-controlled trial followed by a long-term extension study

被引：0

作者：

Tsai, J. ^{[1
]}

Thase, M. ^{[2
]}

Siu, C. ^{[3
]}

Pikalov, A. ^{[1
]}

Loebel, A. ^{[1
]}

机构：

[1] Sunovion Pharmaceut Inc, Med Affairs, Marlborough, MA USA

[2] Univ Penn, Psychiat, Philadelphia, PA 19104 USA

[3] COS & Associates Ltd, Data Sci, Hong Kong, Hong Kong, Peoples R China

来源：

BIPOLAR DISORDERS | 2016年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P-167

引用

页码：121 / 122

页数：2

共 50 条

[31] Long-term Lurasidone Treatment is Not Associated with Clinically Significant Elevations of Prolactin-or Hyperprolactinaemia-related Adverse Events: a Post-HOC Analysis
Inamdar, A.
Dunlop, J.
dos Reis, R. Palma
Andersson, H.
Murthy, V.
EUROPEAN PSYCHIATRY, 2015, 30
[32] Effect of Lurasidone Dose on Recurrence Prevention in Patients With Bipolar I Disorder: Post Hoc Analysis of a Placebo-Controlled Randomized Withdrawal Study
Frye, Mark
Tsai, Joyce
Mao, Yongcai
Pikalov, Andrei
Loebel, Antony
NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S525 - S526
[33] Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies
Sajatovic, Martha
Forester, Brent P.
Tsai, Joyce
Kroger, Hans
Pikalov, Andrei
Cucchiaro, Josephine
Loebel, Antony
JOURNAL OF CLINICAL PSYCHIATRY, 2016, 77 (10) : E1324 - E1331
[34] Evaluation of Anifrolumab Treatment Responses by the Short Form 36 Health Survey Version 2 in SLE: A Post Hoc Analysis of the Placebo-Controlled Phase 3 Long-Term Extension Trial
Strand, Vibeke
Kalunian, Kenneth
Desta, Barnabas
Seo, Caroline
Abreu, Gabriel
Tummala, Raj
Lindholm, Catharina
Al-Mossawi, Hussein
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1150 - 1152
[35] LONG-TERM REMISSION WITH CARIPRAZINE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA: A POST HOC ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, RELAPSE PREVENTION TRIAL
Potkin, Steven
Correll, Christoph
Chang, Cheng-Tao
Szatmari, Balÿzs
Laszlovszky, Istvan
Earley, Willie
SCHIZOPHRENIA BULLETIN, 2017, 43 : S118 - S118
[36] Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial
Lauriello, John
Perkins, Diana O.
JOURNAL OF CLINICAL PSYCHIATRY, 2019, 80 (02)
[37] Effect of lurasidone dose on cognition in patients with schizophrenia: Post-hoc analysis of a long-term, double-blind continuation study
Harvey, Philip D.
Siu, Cynthia O.
Ogasa, Masaaki
Loebel, Antony
SCHIZOPHRENIA RESEARCH, 2015, 166 (1-3) : 334 - 338
[38] Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al
Bettiol, Alessandra
Pregnolato, Francesca
Sciascia, Savino
Emmi, Giacomo
Prisco, Domenico
Meroni, Pier Luigi
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (08)
[39] Safety of lurasidone 40-80mg/d in the long-term treatment of schizophrenia: a post hoc analysis of open label extension study
Liang, S.
Pikalov, A.
Zhao, J.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S326 - S326
[40] Relationship Between Symptomatic and Functional Improvement During Cariprazine Treatment in Patients With Bipolar I Depression: Post Hoc Analysis of a Randomized, Placebo-Controlled Trial
McIntyre, Roger
Tohen, Mauricio
Mattingly, Greg
Vieta, Eduard
Yu, Jun
Nguyen, Huy-Binh
NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 136 - 137

← 1 2 3 4 5 →